

Attorney Docket No.: **ISPH-0500**
Inventors: **Yu et al.**
Serial No.: **09/705,587**
Filing Date: **November 3, 2000**
Page 2

SubD1

- a) preparing a bodily fluid or extract for analytical detection to form a liquid sample;
- b) contacting said liquid sample with a probe complementary to an oligonucleotide so that the probe and the oligonucleotide can form hybrid moieties in said liquid sample, wherein said probe comprises a detectable marker and a binding moiety;
- c) placing said liquid sample in contact with a solid support to which a binding partner of said binding moiety is attached so that said hybrid moieties present in said liquid sample will be attached to said solid support;
- d) removing any oligonucleotide from said liquid sample that has not formed a hybrid moiety;
- e) contacting said liquid sample with a single strand oligonucleotide-specific nuclease under conditions in which probe which is not hybridized to form said double-stranded oligonucleotide moieties hybrid moieties is degraded and thus is no longer attached to said solid support;
- f) removing any unbound detectable marker from said liquid sample; and
- g) detecting a label associated with said marker wherein the presence of said label indicates the presence of said hybrid moieties bound to said solid support wherein detection of said

Attorney Docket No.: **ISPH-0500**
Inventors: **Yu et al.**
Serial No.: **09/705,587**
Filing Date: **November 3, 2000**
Page 3

Subj 1 label at levels above the level characteristic of a liquid sample that was prepared as a blank sample to contain no oligonucleotide indicates the presence of said oligonucleotide in said liquid sample.

C 14. The method of claim 13, wherein said bodily fluid is plasma.

Subj 2 15. The method of claims 13, wherein said oligonucleotide comprises at least one phosphorothioate linkage.

16. The method of claim 13, wherein said oligonucleotide comprises a modification at the 2' position of at least one sugar moiety.

17. The method of claim 16, wherein said 2' modification is a 2'-O-methoxyethyl modification.

Subj 3 18. The method of claim 13, wherein said oligonucleotide comprises at least one modified base.

Attorney Docket No.: **ISPH-0500**
Inventors: **Yu et al.**
Serial No.: **09/705,587**
Filing Date: **November 3, 2000**
Page 4

19. The method of claim 18, wherein said modified base is 5-methylcytosine.

C
20. The method of claim 13, wherein said marker is digoxigenin.

21. The method of claim 13, wherein said label is a colorimetric, radioactive, chemiluminescent, enzymatic or fluorescent label.

22. The method of claim 13, wherein said single-strand specific nuclease is S1 nuclease or mung bean nuclease.--

REMARKS

Claims 1-10 and 12 are pending in this application. Claims 1-10 and 12 have been canceled. New claims 13-22 have been added to incorporate subject matter of the canceled claims and to clarify the instant invention. Support for these new claims can be found throughout the specification as filed.